ReviewClinical & translational immunology2016
Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents.
Review in Clinical & translational immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 67 citations in OpenAlex.
- Chimeric Antigen Receptor Cell Therapy: Empowering Treatment Strategies for Solid Tumors.Current issues in molecular biology · 2025Review
- Review
- Lipid Antigens: Revealing the Hidden Players in Adaptive Immune Responses.Biomolecules · 2025Review
- Macrophages and Pulmonary Fibrosis.Current molecular medicine · 2025Review
- Can invariant Natural Killer T cells drive B cell fate? a look at the humoral response.Frontiers in immunology · 2025Review
- Lung-resident lymphocytes and their roles in respiratory infections and chronic respiratory diseases.Chinese medical journal pulmonary and critical care medicine · 2024Review
- Optimizing iNKT-driven immune responses against cancer by modulating CD1d in tumor and antigen presenting cells.Clinical immunology (Orlando, Fla.) · 2024Review
- A structural perspective of how T cell receptors recognize the CD1 family of lipid antigen-presenting molecules.The Journal of biological chemistry · 2024Review
- A Humanized Mouse Model Coupled with Computational Analysis Identifies Potent Glycolipid Agonist of Invariant NKT Cells.ACS chemical biology · 2024Article
- Conformationally Restricted Analogues of α-Galactosylceramide as Adjuvant in COVID-19 Subunit Vaccine.ACS medicinal chemistry letters · 2023Article
- Review
- Towards a better understanding of human iNKT cell subpopulations for improved clinical outcomes.Frontiers in immunology · 2023Review
- Antibiotics and Carbohydrate-Containing Drugs Targeting Bacterial Cell Envelopes: An Overview.Pharmaceuticals (Basel, Switzerland) · 2022Review
- A humanized mouse model forFrontiers in immunology · 2022Article
- Harnessing invariant natural killer T cells to control pathological inflammation.Frontiers in immunology · 2022Review
- The role of lymphocytes in neonatal encephalopathy.Brain, behavior, & immunity - health · 2021Review
- Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy.Cancer research · 2021Article
- Type I Natural Killer T Cells as Key Regulators of the Immune Response to Infectious Diseases.Clinical microbiology reviews · 2021Review
- Harnessing NKT cells for vaccination.Oxford open immunology · 2021Review
- Natural Killer T (NKT) Cells and Periodontitis: Potential Regulatory Role of NKT10 Cells.Mediators of inflammation · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Certain types of glycolipids have been found to have remarkable immunomodulatory properties as a result of their ability to activate specific T lymphocyte populations with an extremely wide range of immune effector properties. The most extensively studied glycolipid reactive T cells are known as invariant natural killer T (iNKT) cells. The antigen receptors of these cells specifically recognize certain glycolipids, most notably glycosphingolipids with α-anomeric monosaccharides, presented by the major histocompatibility complex class I-like molecule CD1d. Once activated, iNKT cells can secrete a very diverse array of pro- and anti-inflammatory cytokines to modulate innate and adaptive immune responses. Thus, glycolipid-mediated activation of iNKT cells has been explored for immunotherapy in a variety of disease states, including cancer and a range of infections. In this review, we discuss the design of synthetic glycolipid activators for iNKT cells, their impact on adaptive immune responses and their use to modulate iNKT cell responses to improve immunity against infections and cancer. Current challenges in translating results from preclinical animal studies to humans are also discussed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.